Patients must not have received any prior tumor-directed therapy other than surgical intervention and corticosteroids
Recovery from effects of recent surgery, radiotherapy, or chemotherapy\r\n* Patients must be entered within  weeks after surgery performed for either ) initial diagnosis, staging, and/or cytoreduction, or ) (if done) management of recurrent disease in a chemonaive patient\r\n* Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration; continuation of hormone replacement therapy is permitted
Recovery from effects of recent surgery, radiotherapy, or chemotherapy\r\n* Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration; continuation of hormone replacement therapy is permitted\r\n* Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to registration; if the prior therapy was with bevacizumab then at least  weeks after treatment discontinuation must have elapsed prior to treatment on this study
Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to study entry.
Patients are excluded if they had undergone tumor-directed therapy within  months
Any prior therapy directed at the malignant tumor, including radiation therapy, chemotherapy, and biologic/targeted agents must be discontinued at least  days prior to tumor resection for preparing TIL therapy.
Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration
Any other prior therapy directed at the malignant tumor, including biological and immunologic agents, must be discontinued at least three weeks prior to registration
Current treatment with chemotherapy or radiation therapy; any prior therapy directed at the malignant tumor, including biologic and immunologic agents, must be discontinued at least three weeks prior to registration
Patients may be treated on this trial without having received prior medical therapy directed at their GIST, patients who have had prior GIST-directed surgery may enroll provided they have measurable disease
PHASE I: Hormonal therapy directed at treatment for the cancer must be discontinued at least one week prior to enrollment; hormone replacement therapy for symptom management is permitted
PHASE I: Any other therapy directed at treating the cancer including chemotherapy, biologic/targeted agents, and immunologic agents, must be discontinued at least three weeks prior to enrollment
PHASE II: Hormonal therapy directed at treatment for the cancer must be discontinued at least one week prior to enrollment; hormone replacement therapy for symptom management is permitted
PHASE II: Any other therapy directed at treating the cancer including chemotherapy, biologic/targeted agents, and immunologic agents, must be discontinued at least three weeks prior to enrollment
All therapy (except hormonal therapy) directed at the malignant tumor must be discontinued at least  days prior to registration
Any hormonal therapy directed at the malignant tumor must be discontinued at least  days prior to registration; continuation of hormone replacement therapy is permitted
Recovery from effects of any recent surgery, chemotherapy and/or radiation:\r\n* No evidence of active infection requiring antibiotic therapy\r\n* Hormonal therapy being utilized, as an anti-neoplastic treatment must be discontinued at least one week prior to study entry; hormonal replacement therapy for symptom management is allowed\r\n* Any prior therapy directed at the malignancy including biologic or immunologic agents, must have be discontinued at least three weeks prior to study entry
Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration (study enrollment); continuation of hormone replacement therapy is permitted; stable regimens of hormonal therapy i.e. for prostate cancer (e.g. leuprolide, a gonadotropin-releasing hormone [GnRH] agonist), ovarian or breast cancer are not exclusionary
Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to first dose of study drug ( weeks for nitrosoureas or mitomycin C)
Patients must not have received any prior tumor-directed therapy including radiation therapy, chemotherapy (tumor-directed therapy), molecularly targeted agents, or immunotherapy for the treatment of HGG other than surgical intervention
Patients must not have received any prior tumor-directed therapy other than surgical intervention and corticosteroids
Patients who have received any tumor-directed therapy prior to biopsy are not eligible; concurrent treatment with corticosteroids is allowed
Patients must not have received any prior tumor-directed therapy other than surgical intervention and corticosteroids
Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration
Any other prior therapy directed at the malignant tumor, including chemotherapy and immunotherapy, must be discontinued at least three weeks prior to registration; any investigational agent must be discontinued at least  days prior to registration
Recovery from effects of recent surgery, radiotherapy, or chemotherapy:\r\n* Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])\r\n* Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration\r\n* Any other prior therapy directed at the malignant tumor, including chemotherapy, biological/targeted and immunologic agents (including small molecules and murine monoclonal antibodies), must be discontinued at least three weeks prior to registration; chimeric or human or humanized monoclonal antibodies (including bevacizumab) or vascular endothelial growth factor [VEGF] receptor fusion proteins (including VEGF tartrate-resistant acid phosphatase [TRAP]/aflibercept) must be discontinued for at least  weeks prior to registration\r\n* At least  weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy, thoracotomy, video assisted thorascopic surgery [VATS]; minor: central venous access catheter placement, ureteral stent placement or exchange, paracentesis, thoracentesis)
Prior therapy\r\n* Patients must have recurred or progressed following at least one platinum-based chemotherapy regimen\r\n* Patients may have received an unlimited number of prior therapy regimens\r\n* Patients may not have received all of the five choices in the standard therapy arm\r\n* Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration\r\n* Any other prior therapy directed at the malignant tumor, including chemotherapy and radiation therapy, must be discontinued at least  weeks prior to registration; any investigational agent must be discontinued at least  days prior to registration
Any other prior therapy directed at the malignant tumor, including chemotherapy, bevacizumab or other biologic or targeted agents and immunologic agents, must be discontinued at least  days (three weeks) prior to registration.
Appropriate for study entry based on the following diagnostic workup:\r\n* History/physical examination within  days prior to registration\r\n* Imaging of target lesion(s) within  days prior to registration\r\n* Further protocol-specific assessments:\r\n** Recovery from effects of recent surgery, radiotherapy or chemotherapy\r\n** Free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])\r\n** Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration\r\n** Any other prior therapy directed at the malignant tumor including chemotherapy, targeted agents, immunologic agents, and any investigational agents, must be discontinued at least  weeks prior to registration ( weeks for nitrosoureas or mitomycin C) \r\n** Any prior radiation therapy must be completed at least  weeks prior to registration\r\n** At least  weeks must have elapsed since major surgery
Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to the first treatment. Continuation of hormone replacement therapy is permitted.
Patients who are receiving other cancer directed therapy at the time of enrollment
Recovery from effects of recent surgery, radiotherapy, or chemotherapy:\r\n* Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])\r\n* Any hormonal therapy directed at the malignant tumor must be discontinued at least two weeks prior to registration; continuation of hormone replacement therapy is permitted\r\n* Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted and immunologic agents, must be discontinued at least two weeks prior to registration and at least  weeks before day  on trial
Any hormonal therapy directed at malignant tumor must be discontinued at least one week prior to study treatment initiation
Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted therapy and immunologic therapy, must be discontinued at least  weeks prior to study treatment initiation
Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration\r\n* Continuation of hormone replacement therapy is permitted
Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted (non-cytotoxic) agents and immunologic agents, must be discontinued at least three weeks prior to registration
Any myeloma directed therapy within  weeks of registration including plasmapheresis or transfusion
Any hormonal therapy directed at the tumor must be discontinued at least one week prior to initiation of therapy; continuation of hormone replacement therapies is permitted
Any other prior therapy directed at the tumor, including immunologic agents, must be discontinued at least  weeks prior to initiation of therapy
Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration
Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to registration
Any other prior therapy directed at the malignant tumor, including immunologic agents and radiotherapy, must be discontinued at least  weeks prior to first study treatment
Patients who are receiving other cancer directed therapy at the time of enrollment
Prior HER- directed treatment (HER- or EGFR-directed treatment is acceptable).
Any therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to registration
